Active	Status	Sponsor type	Region	Phase	Filter
1 Active 1 Inactive 2 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other Show only owner-sponsored trials	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « August » « 2025 » M T W T F S S 28 29 30 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31   - « August » « 2025 » M T W T F S S 28 29 30 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31   Show only changed items Enrollment:

Advanced Filters

1 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
IBI314 / Innovent Biologics
NCT05172141: A Safety, Tolerability, and Efficacy Study of IBI314 in Patients With Mild to Moderate COVID-19	Terminated	1/2	222	RoW	IBI314(low dose), IBI314(high dose), IBI314(medium dose), Placebo	Innovent Biologics (Suzhou) Co. Ltd.	COVID-19	08/22	01/23

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
IBI314 / Innovent Biologics
NCT05172141: A Safety, Tolerability, and Efficacy Study of IBI314 in Patients With Mild to Moderate COVID-19	Terminated	1/2	222	RoW	IBI314(low dose), IBI314(high dose), IBI314(medium dose), Placebo	Innovent Biologics (Suzhou) Co. Ltd.	COVID-19	08/22	01/23